Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 303-314

  Nair, Kavita V ^a   Tang, Boxiong ^b   Van Den Bos, Jill ^c   Zhang, Vicki ^c   Saseen, Joseph J ^a   Naim, Ahmad ^b   Rahman, Mirza ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b CENTOCOR INC   (United States)

^c MILLIMAN INC   (United States)

Author keywords

Dosing; Expenditures; Infliximab; Rheumatoid arthritis; Utilization

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEPRESSION; DIABETES MELLITUS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INFUSION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OSTEOPOROSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; CLASSIFICATION; DOSE RESPONSE; HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; UNITED STATES; UTILIZATION REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INSURANCE, HEALTH; MEDICARE; PRIVATE SECTOR; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 64249146547     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802598736     Document Type: Article

References (33)

1. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-346
2. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008;214:149-160 (Pubitemid 351160153)
3. Enbrel: Package insert. Thousand Oaks, CA: Immunex; 2006
4. Humira: Package insert. Abbott Park, IL: Abbott Laboratories; 2008
5. Remicade: Package insert. Malvern, PA: Centocor, Inc.; 2007
6. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007;11:1369-1384 (Pubitemid 350200476)
7. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:2750-2762
8. Abarca J, Armstrong EP, Grizzle A, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538-542
9. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21-27
10. Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz L, Dose escalation of the anti-TNF agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007;46: 529-532
11. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36 (Pubitemid 39532839)
12. Wu E, Chen A, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2004;24:2229-2240
13. Weycker D, Yu EB, Woolley MJ. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > 65 years with rheumatoid arthritis. Clin Ther 2005;27:646-656 (Pubitemid 40835976)
14. DeWitt EM, Glick HA, Albert DA, et al. Medicare coverage of tumor necrosis factor a inhibitors as an influence on physicians prescribing behavior. Arch Int Med 2006;166:57-63 (Pubitemid 43063842)
15. Nuijten MJC, Englefreit P, Duijin K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051-1064 (Pubitemid 33701933)
16. Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-393
17. Sidiropoulos P, Bertsias G, Kritikos HD, et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: Dose adjustments are common but not always sufficient to assure a sustained benefit. Ann Rheum Dis 2004;63:144-148 (Pubitemid 38122132)
18. Rahman MU, Strusberg I, Geusens P. Double blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-1238 (Pubitemid 47309743)
19. Berger A, Edelsberg J, Li TT. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-2025 (Pubitemid 41745946)
20. Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Care Res 2005;53:872-878 (Pubitemid 41811128)
21. Flendrie M, Creemers MCW, van Riel PLCM. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology 2007;46:146-149 (Pubitemid 44932803)
22. George D, Kadlubek P, Batra D, et al. Infliximab dose and change in escalation patterns in managed care. Manag Care Interface 2004;Suppl A:5-8
23. Hargrave E, Hoadley J, Thompson J. Coverage and pricing of drugs that can be covered under Part B and Part D. Washington, DC: Medicare Payment Advisory Committee, 2007. Report No. 07-6
24. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept or methotrexate. Am J Manag Care 2003;9:S136-44 (Pubitemid 37345201)
25. Center for Medicare and Medicaid Services. www.cms.hhs.gov/ MedHCPCSGenInfo (accessed on August 22, 2008)
26. Kominski GF, Ripps JC, Laugesen MJ, et al. The California cost and coverage model: analyses of the financial impacts of benefit mandates for the California legislature. Health Serv Res 2006;41:1027-1044 (Pubitemid 43742705)
27. Milliman, Inc., 2008. (Accessed at http://www.milliman.com/expertise/ healthcare/products-tools/health-cost-guidelines/index.php)
28. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep 2008;10:258-264
29. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUESTRA study. Arthritis Res Ther 2008;10:R30
30. Forsblad d'Elia H, Larsen A, Waltbrand E, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003;62:617-623
31. Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care 2001;39:1188-1202 (Pubitemid 33603664)
32. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22
33. Huber PJ. Robust Statistics. New York; John Wiley and Sons, 1981